{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:17:16Z","timestamp":1791389836295,"version":"4.3.3"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.antiviral.2011.06.002","type":"journal-article","created":{"date-parts":[[2011,6,24]],"date-time":"2011-06-24T19:59:19Z","timestamp":1308945559000},"page":"187-194","source":"Crossref","is-referenced-by-count":35,"title":["G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates"],"prefix":"10.1016","volume":"91","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk J.","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Ambrosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Babcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2011.06.002_b0005","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1128\/JVI.78.9.4552-4560.2004","article-title":"Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor","volume":"78","author":"Babcock","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.06.002_b0010","series-title":"Fully human monoclonal antibody 17C7 neutralizes rabies virus endemic to Asia, 19th International Conference on Rabies in the Americas","author":"Babcock","year":"2008"},{"key":"10.1016\/j.antiviral.2011.06.002_b0015","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","article-title":"Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants","volume":"79","author":"Bakker","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.06.002_b0020","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1128\/JVI.65.8.4198-4203.1991","article-title":"Antigenicity of rabies virus glycoprotein","volume":"65","author":"Benmansour","year":"1991","journal-title":"J. Virol."},{"issue":"Pt 2","key":"10.1016\/j.antiviral.2011.06.002_b0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1099\/0022-1317-70-2-291","article-title":"Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein","volume":"70","author":"Bunschoten","year":"1989","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2011.06.002_b0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1099\/0022-1317-61-1-97","article-title":"Molecular basis of rabies virus virulence. I. Selection of avirulent mutants of the CVS strain with anti-G monoclonal antibodies","volume":"61","author":"Coulon","year":"1982","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2011.06.002_b0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1128\/JVI.72.1.273-278.1998","article-title":"An avirulent mutant of rabies virus is unable to infect motoneurons in vivo and in vitro","volume":"72","author":"Coulon","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.06.002_b0040","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1073\/pnas.80.1.70","article-title":"Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus","volume":"80","author":"Dietzschold","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2011.06.002_b0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0042-6822(87)90167-X","article-title":"Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies","volume":"161","author":"Dietzschold","year":"1987","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2011.06.002_b0050","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1128\/JVI.64.8.3804-3809.1990","article-title":"Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine","volume":"64","author":"Dietzschold","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.06.002_b0055","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/hyb.1991.10.547","article-title":"A rabies-specific human monoclonal antibody that protects mice against lethal rabies","volume":"10","author":"Enssle","year":"1991","journal-title":"Hybridoma"},{"key":"10.1016\/j.antiviral.2011.06.002_b0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1099\/0022-1317-48-1-105","article-title":"Use of hybridoma monoclonal antibodies in the detection of antigenic differences between rabies and rabies-related virus proteins. II. The glycoprotein","volume":"48","author":"Flamand","year":"1980","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2011.06.002_b0065","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1016\/S0264-410X(01)00135-9","article-title":"Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis","volume":"19","author":"Hanlon","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2011.06.002_b0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1086\/517179","article-title":"Additional reports of failure to respond to treatment after rabies exposure in Thailand","volume":"28","author":"Hemachudha","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.06.002_b0075","first-page":"360","article-title":"Re-evaluating the burden of rabies in Africa and Asia","volume":"83","author":"Knobel","year":"2005","journal-title":"Bull World Health Organ."},{"issue":"Pt 4","key":"10.1016\/j.antiviral.2011.06.002_b0080","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1099\/0022-1317-64-4-843","article-title":"Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies","volume":"64","author":"Lafon","year":"1983","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2011.06.002_b0085","first-page":"219","article-title":"Investigation of the antigenic structure of rabies virus glycoprotein by monoclonal antibodies","volume":"57","author":"Lafon","year":"1984","journal-title":"Dev. Biol. Stand."},{"key":"10.1016\/j.antiviral.2011.06.002_b0090","series-title":"A Human Monoclonal Antibody to Rabies Virus Provides Protective Neutralizing Activity: Results of a Phase 1 Study, Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"Leav","year":"2010"},{"key":"10.1016\/j.antiviral.2011.06.002_b0095","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1128\/JVI.79.8.4672-4678.2005","article-title":"Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis","volume":"79","author":"Marissen","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.06.002_b0100","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/0264-410X(93)90052-Y","article-title":"Protective activity of a murine monoclonal antibody against European bat lyssavirus 1 (EBL1) infection in mice","volume":"11","author":"Montano-Hirose","year":"1993","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2011.06.002_b0105","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1348-0421.1995.tb03258.x","article-title":"Mapping and characterization of a sequential epitope on the rabies virus glycoprotein which is recognized by a neutralizing monoclonal antibody, RG719","volume":"39","author":"Ni","year":"1995","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2011.06.002_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JVI.62.1.1-7.1988","article-title":"Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence","volume":"62","author":"Prehaud","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.06.002_b0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/375247","article-title":"Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies","volume":"188","author":"Prosniak","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.06.002_b0120","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1172\/JCI114260","article-title":"Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies","volume":"84","author":"Schumacher","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2011.06.002_b0125","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1128\/JVI.53.3.926-934.1985","article-title":"Rabies virulence. effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein","volume":"53","author":"Seif","year":"1985","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.06.002_b0130","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2006.12.031","article-title":"Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates","volume":"25","author":"Sloan","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2011.06.002_b0135","series-title":"Consultation on a Rabies Monoclonal Antibody Cocktail for Rabies Post Exposure Treatment","year":"2002"},{"key":"10.1016\/j.antiviral.2011.06.002_b0140","unstructured":"WHO, 2005. World Health Organization \u2013 Rabies Fact Sheet 99, revised September 2005."},{"key":"10.1016\/j.antiviral.2011.06.002_b0145","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1073\/pnas.75.8.3938","article-title":"Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants","volume":"75","author":"Wiktor","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2011.06.002_b0150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0264-410X(89)90010-8","article-title":"Failure of rabies postexposure treatment in Thailand","volume":"7","author":"Wilde","year":"1989","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2011.06.002_b0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/clinids\/22.2.228","article-title":"Failure of postexposure treatment of rabies in children","volume":"22","author":"Wilde","year":"1996","journal-title":"Clin. Infect. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211003433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211003433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T17:02:26Z","timestamp":1592672546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354211003433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0166354211003433"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2011.06.002","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}